.Pharmacolibrary.Drugs.ATC.L.L01EC01

Information

name:Vemurafenib
ATC code:L01EC01
route:oral
n-compartments2

Vemurafenib is an oral small molecule inhibitor of the BRAF serine-threonine kinase, specifically targeting the BRAF V600E mutation. It is primarily approved for the treatment of unresectable or metastatic melanoma with BRAF V600E mutation and is currently used clinically for this indication.

Pharmacokinetics

Population pharmacokinetic analysis in adult cancer patients (melanoma), both sexes, oral dosing at steady state.

References

  1. Zhang, W, et al., & Grippo, JF (2017). Clinical Pharmacokinetics of Vemurafenib. Clinical pharmacokinetics 56(9) 1033–1043. DOI:10.1007/s40262-017-0523-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28255850

  2. Wang, H, et al., & Ivaturi, V (2020). Population Pharmacokinetics of Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E-Mutant Astrocytomas. Journal of clinical pharmacology 60(9) 1209–1219. DOI:10.1002/jcph.1617 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32476174

Revisions

Generated at 2025-07-21T18:21:10Z by OpenModelicaOpenModelica 1.25.1 using GenerateDoc.mos